|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Boston University |
|---|---|
| Information provided by: | Boston University |
| ClinicalTrials.gov Identifier: | NCT00382538 |
Purpose
Mid-second trimester medical terminations of pregnancy require admission to the hospital for the length of time it takes a woman to abort. The current protocol at BMC uses intra-amniotic digoxin injection the day prior to admission. The following day, the woman is admitted and given sequential doses of misoprostol until delivery occurs. The average length of time between the first dose of misoprostol and delivery is 12 hours, requiring most women to stay overnight. This is a randomized, placebo-controlled, double-blinded study designed to determine whether adding mifepristone significantly reduces the induction interval time (time between starting the first misoprostol and delivery) required for a second trimester termination.
| Condition | Intervention |
|---|---|
|
Abortion, Induced Abortion, Second Trimester |
Drug: Addition of mifepristone 200 mg 24 hours before induction |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy |
| Estimated Enrollment: | 64 |
| Study Start Date: | March 2005 |
| Study Completion Date: | November 2006 |
| Primary Completion Date: | November 2006 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 16 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Massachusetts | |
| Boston Medical Center | |
| Boston, Massachusetts, United States, 02118 | |
| Principal Investigator: | Lynn Borgatta, MD, MPH | Boston University |
More Information
| Study ID Numbers: | 24597 |
| Study First Received: | September 28, 2006 |
| Last Updated: | October 3, 2008 |
| ClinicalTrials.gov Identifier: | NCT00382538 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
mifepristone induction abortion injection, intra-amniotic |
|
Abortifacient Agents, Steroidal Contraceptives, Postcoital, Synthetic Contraceptive Agents Hormone Antagonists Contraceptives, Oral Physiological Effects of Drugs Contraceptive Agents, Female Hormones, Hormone Substitutes, and Hormone Antagonists Mifepristone |
Reproductive Control Agents Luteolytic Agents Contraceptives, Postcoital Pharmacologic Actions Therapeutic Uses Abortifacient Agents Menstruation-Inducing Agents Contraceptives, Oral, Synthetic |